MaaT Pharma’s products, Microbiome Ecosystem Therapies (MET), are high-diversity, high-richness, indication-specific products aiming to leverage the full functional diversity of a large microbiome ecosystem.
MaaT Pharma developed one of the first global platform to develop and manufacture MET-N, native, donor-derived products. MET-N are intended as symbiosis-restoring therapies in indications where patients present an often iatrogenic, severe dysbiosis.
More recently, MaaT Pharma has leveraged the knowledge accumulated from native products to develop a new generation of products, MET-C, which can be rationally designed from patients-derived data and cultured at large scale. MET-C are intended as immune-modulating therapies in patients with solid tumors receiving immune checkpoint inhibitors.